

# CEO BOARD UPDATE

Seth Berkley, CEO



Credit: Gavi/Isaac Griberg.



Board meeting  
24–25 June 2020

[www.gavi.org](http://www.gavi.org)

# 1

## Key developments in global landscape


---

Board meeting  
24–25 June 2020

# COVID-19: an unprecedented global challenge

---

January–June 2020: spread to 214 countries and territories



Cumulative confirmed cases  
(as of 17 June 2020)

Credit: COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU): <https://coronavirus.jhu.edu/map.html>

Board meeting  
24–25 June 2020

# COVID-19: devastating global impact

---

- **WHO data on health impact**
  - **Global deaths: >440,000; global cases: >8 million**
  - **Immunisation programmes and other essential health services disrupted**
- **OECD Economic Outlook, June 2020: most severe economic recession in nearly 100 yrs**
  - **Two scenarios possible:**
    - If 2nd wave avoided: economic activity falls 6% in 2020; unemployment climbs to >9%
    - If 2nd wave hits in 2020: economic output plummets >7% this year; unemployment nearly doubles to 10%
- **Disproportionate impact on vulnerable communities**
  - **OCHA: world's most fragile places will see disease peak in 3–6 months**
  - **World Bank: first net rise in global poverty in >20 yrs**

# 2

## Gavi replenishment and the Global Vaccine Summit 2020

---

Board meeting  
24–25 June 2020

# Gavi@20: World Economic Forum, Davos

---



January 2000



January 2020

Board meeting  
24–25 June 2020

# Global Vaccine Summit 2020: 4 June 2020



## Global solidarity, recognition of Gavi's mission of equitable access

- 42 heads of state, including all 7 of G7
- 52 countries represented, including heads of state and representatives of 19 of the G20
- 14 Gavi-supported countries participated
- >180,000 people watched online

# Pledges and commitments

---

- Foundations laid at World Economic Forum and EC Global Coronavirus Response Pledging Conference
- Additional US\$ 8.8 billion raised for Gavi's next strategic period (2021–2025), for a total of US\$ 10.5 billion available for Gavi 5.0
- Close to US\$ 1 billion included for Gavi through IFFIm
- Private sector partners pledged more than US\$ 70 million to strengthen Gavi programmes
- More than US\$ 0.5 billion available to jumpstart COVID-19 vaccine purchase (Gavi COVAX AMC)
  - MOU for 300 million doses of first COVID-19 vaccine for COVAX Facility announced



# Manufacturers commit to supply HPV vaccine for 84 million girls

---



- Five manufacturers pledged to ramp up human papillomavirus (HPV) vaccine supply for Gavi-supported countries
- New supply to protect 84 million girls, instead of 50 million girls, from 2021–2025
- An estimated 1.4 million future deaths from cervical cancer will be prevented


# 3

## COVID-19 response: Gavi's role

Board meeting  
24–25 June 2020

# Gavi-eligible countries account for ~11% of global COVID-19 cases\*

COVID-19 cases by Gavi-eligible country



\* World Health Organization data as of 16 June 2020

- **70** (out of 73) Gavi-eligible countries have reported cases
- **824,259** confirmed cases
- **20,641** deaths

Source:

<https://www.gavi.org/sites/default/files/document/2020/Gavi-COVID-19-Situation-Report-11-20200616.pdf>


Board meeting  
24–25 June 2020

# Prioritising immunisation, an essential health service, during COVID-19 pandemic

---

## Impact on Gavi-supported countries

- 66% of introductions/campaigns delayed or at risk
- Uptake of routine services reduced
- Global supply disruptions
- Increase in vaccine hesitancy and misinformation
- Outbreaks of vaccine preventable diseases




## Gavi's immediate and interim programmatic response



- Up to US\$ 200 million available for immediate response and preparedness; flexibilities in policies and processes
- Maintaining and restoring immunisation
- WHO pulse surveys
- Alliance-wide engagement on addressing vaccine hesitancy and misinformation
- Epidemic response

# WHO survey: immunisation services most at risk of disruption

## Countries' top 10 most frequently reported service disruptions\*

- 
1. **Immunisation services** (outreach: 73%; facility-based: 63%)
  2. **Rehabilitation services** (69%)
  3. **Dental services** (69%)
  4. **Malaria prevention campaigns** (ITN: 68%; SMC: 65%, IRS: 62%)
  5. **NCD diagnosis and treatment** (65%)
  6. **Family planning and contraception** (62%)
  7. **Treatment for mental health disorders** (62%)
  8. **Cancer diagnosis and treatment** (61%)
  9. **Antenatal care** (60%)
  10. **Sick child services** (60%)

\* Comprehensive online survey on COVID-19 impact on 25 essential health services across the life course to understand the extent of disruption across all services; assess prevailing mitigation strategies for maintaining services; identify priorities and technical assistance. Reporting period: ~Mar.–May 2020. Early results from 52 countries (8 Jun. 2020). Survey closing date: 15 Jun. 2020.



# Building confidence in vaccines during a pandemic

- Sabin-Aspen report (June 2020): *“most powerful way to increase vaccination is through provider recommendations”*
- No one size fits all; challenges are locally contextualised and specific, requiring holistic approach
- What we’re doing:
  - working as an Alliance to provide support – Demand Hub
  - stepping up collaboration with civil society
  - taking action with technology platforms
  - connecting countries with locally relevant, practical tools to address vaccination hesitancy and empower health workers
  - developing strategy to address “infodemic” of misinformation



# Intensified focus on demand, communities & gender

- COVID-19 highlights need for strong **demand generation systems** to build vaccine confidence and community resilience
- Economic fallout of pandemic exacerbates **socio-economic and gender disparities** due to conflict, fragility, migration and urbanisation
- **Communities and civil society organisations** hold key to engaging with immunisation



GENERATING EVIDENCE



ADVOCATING STRATEGICALLY



BUILDING CAPACITY



TRANSFORMATIVE INTERVENTIONS



BUILDING PARTNERSHIPS




Accelerating digital training and gender-responsive learning approaches for frontline health workers



New countries to empower adolescent girls with healthy behaviours



Expansion of “Successful Beginning” to at least one additional country



Social listening and engagement in West and Central Africa



Agreement to facilitate work in fragile and emergency settings to reach vulnerable communities



Data insights and digital engagement

Board meeting  
24–25 June 2020



# Exponential growth of Gavi's digital footprint

- Fresh content daily on #VaccinesWork platform yielded **1 million total page views** since mid-March
- **1.74 million** impressions of Gavi Tweets from 1–5 June
- #VaccinesWork and #GVS2020 were **top trending hashtags** on Twitter in Switzerland
- **Top mentions using #GVS2020**: PM Jakobsdóttir, PM Johnson, PM Macron, PM Modi, Minister Tadesse, Taoiseach Varadkar, Dr Tedros and Melinda Gates
- **>3 million** video views on Facebook in first week of June
- **COVID-19 page** on Gavi.org with articles, dashboard, key news, reprogramming totals, sitreps, partner links



#VACCINESWORK

1 · Politics · Trending  
**#VaccinesWork**  
8,096 Tweets

2 · Politics · Trending  
**#GVS2020**  
4,696 Tweets

**Gavi, the Vaccine Alliance** ✓  
@gavi

Gavi, the Vaccine Alliance, helps vaccinate debilitating diseases. #VaccinesWork

Geneva, Switzerland [gavi.org](https://gavi.org)

1,314 Following 119.8K Followers



Gavi, the Vaccine Alliance was live.  
June 4 at 1:44 PM · 🌐

COVID-19 | COUNTRY PORTAL | DONATE | GLOBAL VACCINE SUMMIT | CAREERS | ETHICS HOTLINE | CONTACT US | EN 1/18

Gavi

OUR ALLIANCE | PROGRAMMES & IMPACT | INVESTING IN GAVI | #VACCINESWORK | NEWS & RESOURCES

## Responding to COVID-19

**DASHBOARD**

**GAVI'S RESPONSE**

- Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC), an investment opportunity

With COVID-19 now reported in almost all Gavi-eligible countries, the Vaccine Alliance is providing immediate funding to health systems, enabling countries to protect health care workers, perform vital surveillance and training, and purchase diagnostic tests.

Gavi and its Alliance partners are also working to maintain ongoing immunisation programmes, avoiding future deaths resulting from a range of preventable diseases including measles, yellow fever, polio, meningitis, pneumonia and diarrhoea.

Gavi is committed to securing a global response to COVID-19 that is effective and fair, using its unique expertise to help identify and rapidly accelerate development, production and delivery of COVID-19 vaccines so that anyone that needs them, gets them.

**SITUATION REPORTS**

A fortnightly update concerning the impact of and response to the COVID-19 pandemic in Gavi-supported countries.


- #10 (02 June 2020)
- #9 (19 May 2020)
- #8 (05 May 2020)
- #7 (28 April 2020)
- #6 (21 April 2020)
- #5 (14 April 2020)

**PARTNER LINKS**



# Enabling fair and equitable access to COVID-19 vaccines

## Access to COVID-19 Tools (ACT) Accelerator structure and Vaccines Pillar



Board meeting  
24–25 June 2020

# COVID-19 Global Vaccine Access Facility

---

## Primary objective

**Accelerate global equitable access of appropriate, safe and efficacious vaccines**

## Supporting objectives

- **Secure supply rapidly** through at risk scale-up of manufacturing
- **Reduce demand uncertainty and predictability** as a barrier to manufacturing scale-up
- Have an **actively managed portfolio** of vaccines to use facilities and supplies most efficiently



## Benefits to all countries

- Access to a large portfolio of affordable COVID-19 vaccines
- Higher global coverage → protection against cross-border transmission → economic recovery

## Benefits to lower-income countries

- Financing support for LICs/LMICs for vaccine procurement, delivery and technical assistance

# Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi COVAX AMC)

---



- **Part of new COVAX Facility** – the Gavi COVAX AMC is the official development assistance (ODA)-supported financing instrument of the COVAX Facility
- **ODA support to high-risk populations in lower-income countries (LICs/LMICs)**
- **Investment opportunity of US\$ 2 billion as seed funding**
- **Incentivise manufacturers through guarantees to ensure sufficient global capacity before vaccines are licensed**
- **LICs/LMICs get access to vaccines as soon as they become available**
- **Doses allocated per WHO's Global Allocation Framework**

# 4

## Reporting back on previous Board decisions

Board meeting  
24–25 June 2020

# 2019: Continued ramp-up in scale of programme and support to countries

---

- **59 vaccine introductions – exceeded target of 56**
- **A record US\$ 331 million in HSS disbursements**
  - Growth since 2009 and increasingly targeted to immunisation bottlenecks
- **CCEOP: 20,000 units procured (target met)**
  - US\$ 10.5 million savings achieved
  - Significant achievements gained in market health
- **Co-financing performance reached an all-time high**
  - Timely fulfillment of obligations by 49 of 50 countries; only 1 defaulting country

# Successful conclusion of Pneumococcal AMC pilot

---

## ADVANCE MARKET COMMITMENT FOR PNEUMOCOCCAL VACCINES

ANNUAL REPORT  
1 JANUARY–31 DECEMBER 2019


*PREPARED BY THE AMC SECRETARIAT OF GAVI, THE VACCINE ALLIANCE*

- 10-year pilot Advance Market Commitment (AMC) for pneumococcal vaccines ends as planned in December 2020
- Estimated 225 million\* children across 60 countries protected against leading cause of pneumonia
- Third supplier to AMC makes PCV available at US\$ 2.00 per dose (43% reduction from Gavi price at AMC start)

\* Projected data. Actual 2019 data will become available in July/August 2020. From programme start through end 2018, more than 183 million children were immunised with AMC-supported pneumococcal vaccines. Coverage for pneumococcal vaccines in low-income countries is higher than the global average.

Board meeting  
24–25 June 2020

# Digital immunisation platform helps Sindh, Pakistan, respond during pandemic




- In Pakistan, informal urban settlements were first to feel COVID-19 impact
- In Sindh province, the Gavi-supported *Zindagi Mehfooz* (“Safe Life”) digital immunisation registry helps >2,400 registered vaccinators protect 2.9 million children
- Missed appointments logged to enable geographic targeting of catch-up programmes
- App trains health workers to prevent COVID-19 transmission

# Measles: “tracer” for under-served communities

## Number of reported measles cases (6-month period)

Top 10	
Country	Cases
DR Congo	19,166
Nigeria	6,371
Brazil	6,069
Kazakhstan	4,755
India	4,516
Uzbekistan	4,508
Philippines	4,424
Central African Republic	4,194
Bangladesh	3,627
Ethiopia	2,434



*Because measles is highly infectious, its presence serves as a tracer (the “canary in the coal mine”) of inadequate coverage and gaps in the health system.*

**–Immunisation Agenda 2030: A global strategy to leave no one behind**

Based on data received 2020-06 - Surveillance data from 2019-11 to 2020-04


\* Dr. Katherine O'Brien, Director of WHO Immunization, Vaccines and Biologicals Department, report to SAGE (31 March 2020)

Board meeting  
24–25 June 2020



# COVID-19: drops in measles-rubella routine coverage, suspension of preventive campaigns


## Bangladesh case study



- Ministry of Health released guidelines for conducting immunisation in the context of COVID-19
- Training of 26,000 frontline health care workers on infection prevention and control, communication strategies (by end June 2020)
- Ongoing discussions on resumption of modified MR preventive campaign and opportunities for integration

# “Measles deaths will rebound if immunisation programmes fail”\*

\*Dr. Katherine O'Brien, Director of WHO Immunization, Vaccines and Biologicals Department, report to SAGE (31 March 2020)



# Impact of COVID-19 on polio: ensuring hard-won gains not lost

---



*Credit: UNICEF/Chad*

- GPEI paused polio vaccination activities; AFP and environmental surveillance continued
- Ongoing outbreaks in 16 countries: marked increase over 2019 case numbers
- Risks in maintaining status quo; opportunity for new strategies coming out of lockdowns
- Mitigating impact of COVID-19
- Implications for GPEI's Endgame Strategy, timelines and budget

## YEAR-TO-DATE 2020

Jan 1 – Jun 17, 2020

**64** WPV **135** cVDPV

## YEAR-TO-DATE 2019

Jan 1 – Jun 17, 2019

**51** WPV **47** cVDPV

Board meeting  
24–25 June 2020

# Outbreaks in the context of COVID-19: 2020

---

## Cholera outbreaks

- **Bangladesh, Cameroon, DRC, Ethiopia, Mozambique, Uganda**
  - In 2020, 3.4 million OCV doses shipped to Bangladesh, Cameroon, DRC, Mozambique and Uganda for emergency response
  - In 2020, 1.9 million OCV doses shipped to Bangladesh and Malawi for preventive hotspot vaccination

## Diphtheria outbreak

- **Yemen**

## Ebola outbreak

- **Democratic Republic of the Congo (DRC)**
  - 11th outbreak since records began; new cases in Équateur Province
  - As of 13 June 2020, >2,500 people vaccinated with ERVEBO® (Merck) vaccine in Équateur Province
  - To date, >308,000 people in DRC reached with Gavi-funded vaccines

## Measles outbreaks

- **Angola, Bangladesh, Brazil, Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, DRC, Ethiopia, Kenya, Nigeria, Tajikistan, Uzbekistan**
  - Measles & Rubella Initiative Outbreak Response Fund supported ~800,000 doses for Chad


## Yellow fever outbreaks

- **Ethiopia, South Sudan, Uganda**
  - In 2020, Gavi-funded stockpile doses shipped to Ethiopia (~790,000) and Uganda (>1.8 million)




# Impact of COVID-19 on Malaria Vaccine Implementation Programme (MVIP)


6 of 11 MVIP districts affected



5 of 7 MVIP regions affected



6 of 8 MVIP counties affected



## Vaccination programmes continue in Malawi, Ghana, Kenya

- COVID-19 mitigation measures being applied

## Known impact of COVID-19

- Delays in conducting New Vaccine Post-Introduction Evaluation (PIE) in 3 countries (originally set to be completed by Q2 2020); no new dates

## Potential impact of COVID-19


- Delays in conducting 2nd household surveys (originally set to be completed in 2 countries by Q3 2020)
- Timelines for data collection and readiness for policy review (at the earliest in Q1 2022) currently maintained

## Too early to assess net budgetary impact

# RTS,S update: progress on third-party de-risk for malaria bulk antigen manufacturing


---

- **December 2019: Board asked Secretariat to identify partner(s) and develop a risk-share for continued RTS,S bulk antigen manufacture pending WHO policy and Gavi investment decisions**
  - **Secretariat in discussion with MedAccess alongside WHO, GSK, PATH**
  - **Impact of COVID-19 on all organisations has shifted timelines**
    - GSK agreed to extended deadline to enable due diligence and negotiations
- **MSDC meeting expected Q3/4 2020 depending on progress**



# Strengthening yellow fever (YF) diagnostic capacity in Africa: an update

---



- 20 out of 24 eligible countries approved for YF diagnostic support; 1 application under IRC review
- UNICEF Supply Division (SD) secured reagents and equipment for current first-line YF test protocol, despite COVID-19 challenges
- Outreach of manufacturers to submit expressions of interest for test kit validation review; commercialisation of test kits underway
- Progress on fit-for-purpose lab data: guiding vaccination programme decision-making on RI introduction, preventive campaigns and outbreak responses

# Ensuring immunisation gains in fragile countries: Yemen, Syria

---

## Yemen

- Seminal Alliance mission (Feb. 2020) to Sanaa, Aden
- Immunisation programme strongly supported by North, South authorities
- Agreement on an EPI review in 2020 to inform longer-term strategy, prioritisation and planning

## Syria

- Partnership Framework Agreement signed (May 2020)



Visit to central cold store, Yemen



Visit with Ministry of Health, Paediatric Hospital, Yemen



Credit: UNICEF/Syria2019/Khuder Al-Issa



# Preparing for transition: Gavi 4.0 to Gavi 5.0

---

- **Navigating complex transition between two strategic periods: 2016–2020 and 2021–2025**
- **Reviewing workstreams to deliver effectively against mandate (eg, cross-Secretariat oversight of “Innovation”)**
- **Gavi 4.0 spend**
  - prior to COVID-19 disruptions, total expenditures were on track (at ~80% of forecast)
  - closely monitoring COVID-19 implications; will be reflected in upcoming forecasts
- **Moving goalposts to reflect COVID-19 reality**
  - Gavi 5.0 operationalisation
  - Gavi 5.0 M&E framework targets

## Organisational review

- Secretariat leadership team workshops in Q1; COVID-19 triggered pause
- Plan to restart in Q3
- Need to factor in COVID-19 impact on programmes and additional activities (eg, Gavi COVAX AMC)

# 5

## Alliance and Secretariat update

Board meeting  
24–25 June 2020

# Resilience of Secretariat in lockdown

---

## **Robust IT solutions enabled seamless, uninterrupted collaboration**

- Rapid transition to a virtual donor pledging conference
- Continued engagement of stakeholders across the globe despite travel ban

## **Proactive and vigilant human resources and operations planning**

- DC and Geneva office reopened on 15 June for up to 20% staff, based on needs (ie, printing) but default still work at home
- Few COVID-19 cases among staff; all recovered

## **Keeping staff connected**

- News bulletins, wellness programme, frequent virtual all-staff meetings, staff pulse surveys, morning radio show, Gavi@Home group to share stories of home working, intranet

# Gavi Secretariat update

---

## New senior hires



**Hannah Burris**  
Chief of Staff



**Olly Cann**  
Director  
Communications



**Brenda Killen**  
Director  
Governance



**Derrick Sim**  
Director  
Vaccine Supply & Demand

Board meeting  
24–25 June 2020

# With gratitude to Phil Armstrong ....

---



**For his leadership  
and dedicated service  
to Gavi's governance  
from August 2015  
through September 2020**

Board meeting  
24–25 June 2020

# THANK YOU

---



*Credit: Gavi/Isaac Griberg*



[www.gavi.org](http://www.gavi.org)